Loargys® (pegzilarginase) receives positive opinion by the CHMP for treatment of arginase 1 deficiency
Stockholm, October 13, 2023: Immedica today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D) in patients two years and older. The positive opinion from the CHMP is now referred to the European Commission for a decision. Anders Edvell, CEO of Immedica commented: “Today’s announcement demonstrates significant progress towards providing the first disease modifying treatment for ARG1-D.